经皮射频消融治疗乳腺癌肝转移疗效的Meta分析

A Meta analysis of the efficacy of percutaneous radiofrequency ablation for breast cancer liver metastases

目的:通过采用Meta分析的方法来研究经皮射频消融(PRFA)治疗乳腺癌肝转移(BCLM)患者的不同年限总生存率(OS)、完全消融率(CA)、局部复发率(LTP),以期获得PRFA治疗BCLM的临床疗效的循证医学相关依据。方法:系统检索PubMed、Cochrane library、Embase、中国知网、万方数据库从建库至2023年9月以来关于PRFA治疗BCLM的队列研究或病例对照研究。依据制定的纳入及排除标准来筛选文献,完成文献质量评价并提取数据,利用Stata 15.1软件进行统计分析并绘制森林图。结果:本研究共纳入10项病例对照研究及队列研究,PRFA治疗BCLM患者为312例,1、2、3、5年OS分别为86%、57%、56%、33%,CA为94%,LTP为16%。结论:本Meta分析表明,PRFA治疗BCLM具有良好的疗效。

Objective:To study the overall survival rate(OS),complete ablation rate(CA),and local tumor progression rate(LTP)in different years after percutaneous radiofrequency ablation(PRFA)for breast cancer liver metastases(BCLM)by Meta-analysis,in order to obtain the basis of evidence-based medicine for the clinical efficacy of PRFA in BCLM.Methods:Cohort studies or case-control studies on PRFA in the treatment of BCLM were systematically searched from PubMed,Cochrane library,Embase,CNKI and Wanfang from database inception to September 2023.References were screened according to inclusion and exclusion criteria,quality assessment was carried out,and data were extracted.Stata 15.1 software was used for statistical analysis and forest map drawing.Results:A total of 10 case-control studies and cohort studies were included.A total of 312 patients were treated with PRFA for BCLM,with OS at 1,2,3 and 5 years of 86%,57%,56%,33%,CA of 94%and LTP of 16%.Conclusion:The Meta-analysis indicates that PRFA is effective in the treatment of BCLM.